Stock News

Medicines Co (MDCO) Holder Camber Capital Management Lifted Its Position by $12.80 Million; Abbvie (ABBV) Stock Price Declined While Grandfield & Dodd Cut Its Holding

AbbVie Inc. (NYSE:ABBV) Logo

Grandfield & Dodd Llc decreased its stake in Abbvie Inc (ABBV) by 26.83% based on its latest 2018Q1 regulatory filing with the SEC. Grandfield & Dodd Llc sold 3,383 shares as the company’s stock declined 16.83% with the market. The institutional investor held 9,227 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $873,000, down from 12,610 at the end of the previous reported quarter. Grandfield & Dodd Llc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $149.76B market cap company. The stock decreased 0.86% or $0.86 during the last trading session, reaching $98.91. About 8.06M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 13, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 11/04/2018 – Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab); 05/04/2018 – Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe; 05/04/2018 – BIOGEN – UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE, ON A COUNTRY-BY-COUNTRY BASIS; 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE…; 26/04/2018 – AbbVie: Tender Offer is Part of $10B Buyback Program Announced on Feb 15, 2018; 31/05/2018 – Phase l/Il Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting; 30/04/2018 – FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and; 12/04/2018 – Emerging Advanced Resources Could Rock The Canadian Cannabis Industry; 23/05/2018 – Merck: Keytruda Has Shown Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials; 22/03/2018 – BerGenBio to Present Overview of Phase Il Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

Stephen Dubois increased its stake in Medicines Co (MDCO) by 25% based on its latest 2018Q1 regulatory filing with the SEC. Camber Capital Management Llc bought 400,000 shares as the company’s stock rose 4.51% while stock markets declined. The hedge fund run by Stephen Dubois held 2.00M shares of the major pharmaceuticals company at the end of 2018Q1, valued at $65.88 million, up from 1.60M at the end of the previous reported quarter. Camber Capital Management Llc who had been investing in Medicines Co for a number of months, seems to be bullish on the $2.67B market cap company. The stock increased 0.19% or $0.07 during the last trading session, reaching $36.28. About 684,845 shares traded. The Medicines Company (NASDAQ:MDCO) has declined 16.45% since June 13, 2017 and is downtrending. It has underperformed by 29.02% the S&P500. Some Historical MDCO News: 25/04/2018 – Acticor Biotech Announces That the European Medicines Agency Clears the Route for a Phase II of Its ACT017 Product in Stroke; 03/04/2018 – Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer; 23/04/2018 – MLNT PRESENTS DATA ON VABOMERE TANGO II IN VULNERABLE PATIENTS; 27/03/2018 – INDOCO REMEDIES LTD – UNITED KINGDOM – MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (UK-MHRA) INSPECTED CO’S GOA DRUG MANUFACTURING FACILITY; 23/05/2018 – BSE Mumbai Bourse: Results from Kashyap Tele-Medicines for Jan 01 to Mar 31; 01/05/2018 – AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab; 01/05/2018 – BioCryst Receives European Medicines Agency Approval for ALPIVAB™ for the Treatment of Influenza; 23/03/2018 – EU MEDICINES AGENCY RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY CLVS.O OVARIAN CANCER DRUG RUBRACA; 03/04/2018 – REGENERON PHARMACEUTICALS INC REGN.O – EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED FOR REVIEW AN APPLICATION FOR DUPIXENT; 27/03/2018 – Homology Medicines Announces Pricing of Initial Public Offering

Among 24 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 12 Hold. Therefore 38% are positive. Abbvie Inc had 96 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $10 target in Friday, September 15 report. The stock of AbbVie Inc. (NYSE:ABBV) earned “Outperform” rating by Raymond James on Friday, September 2. The rating was downgraded by Morgan Stanley on Wednesday, June 8 to “Equal-Weight”. The rating was maintained by BMO Capital Markets with “Market Perform” on Thursday, November 16. The firm has “Mkt Perform” rating given on Tuesday, October 18 by Leerink Swann. Cowen & Co downgraded AbbVie Inc. (NYSE:ABBV) on Monday, June 6 to “Market Perform” rating. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Monday, July 17 by Jefferies. The firm has “Buy” rating by Argus Research given on Monday, June 11. The rating was maintained by Morgan Stanley on Monday, April 30 with “Equal-Weight”. The stock of AbbVie Inc. (NYSE:ABBV) earned “Hold” rating by BMO Capital Markets on Wednesday, October 11.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: which released: “Premarket analyst action – healthcare” on May 24, 2018, also with their article: “Major Pharmaceuticals Scare Off Short Sellers” published on June 12, 2018, published: “The 30+1 Portfolio: An Average Investor’s Reasoning For Buying A Stock – AbbVie, Absolutely” on June 07, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: and their article: “AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis …” published on June 13, 2018 as well as‘s news article titled: “Is AbbVie Inc. (ABBV) a Buy?” with publication date: May 30, 2018.

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It dived, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. 154,936 are held by Fin Engines Limited Liability Corporation. Dreman Value Mgmt L L C invested 0.9% of its portfolio in AbbVie Inc. (NYSE:ABBV). Foyston Gordon Payne Inc owns 12,275 shares. Stratos Wealth Prtnrs invested in 83,265 shares or 0.33% of the stock. Sadoff Invest Ltd Limited Liability Company stated it has 0.03% in AbbVie Inc. (NYSE:ABBV). Moreover, Earnest Prns Ltd Co has 0% invested in AbbVie Inc. (NYSE:ABBV). Northstar Inv Advsrs Limited Liability invested in 0.24% or 11,843 shares. Norris Perne And French Llp Mi holds 29,531 shares or 0.41% of its portfolio. Principal Grp owns 2.90 million shares. Hemenway Tru Limited Liability reported 31,366 shares or 0.56% of all its holdings. Capital Ca reported 0.39% stake. Clear Harbor Asset Ltd Llc has invested 0.19% in AbbVie Inc. (NYSE:ABBV). Mckinley Management Limited Liability Delaware invested 1.73% of its portfolio in AbbVie Inc. (NYSE:ABBV). Lsv Asset Management invested 0.92% of its portfolio in AbbVie Inc. (NYSE:ABBV). Calamos Advsr Ltd Liability Corp reported 1.13M shares or 0.69% of all its holdings.

Since December 14, 2017, it had 0 insider purchases, and 10 selling transactions for $33.62 million activity. $8.31 million worth of AbbVie Inc. (NYSE:ABBV) was sold by CHASE WILLIAM J on Wednesday, February 28. On Monday, December 18 the insider RICHMOND TIMOTHY J. sold $8.57 million. Michael Robert A. had sold 992 shares worth $119,351 on Monday, February 19. ALBAN CARLOS sold 83,574 shares worth $9.57 million. On Wednesday, February 28 Schumacher Laura J sold $2.95M worth of AbbVie Inc. (NYSE:ABBV) or 25,000 shares. GONZALEZ RICHARD A also sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 EPS, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98B for 12.55 P/E if the $1.97 EPS becomes a reality. After $1.87 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Grandfield & Dodd Llc, which manages about $885.55 million and $896.50 million US Long portfolio, upped its stake in Albemarle Corp (NYSE:ALB) by 7,210 shares to 86,755 shares, valued at $8.05M in 2018Q1, according to the filing. It also increased its holding in Sanofi (NYSE:SNY) by 15,800 shares in the quarter, for a total of 266,849 shares, and has risen its stake in Brunswick Corp (NYSE:BC).

Since December 15, 2017, it had 0 buys, and 3 selling transactions for $1.06 million activity. The insider MEANWELL CLIVE sold 136,250 shares worth $3.71 million. The insider Spigelman Melvin K sold 7,500 shares worth $241,500. On Tuesday, January 16 the insider KESSLER ARMIN M sold $574,200.

More recent The Medicines Company (NASDAQ:MDCO) news were published by: which released: “Rounds Report: Melinta Rallied While Novavax Experienced Significant Insider Purchases” on June 06, 2018. Also published the news titled: “Rounds Report: Melinta Rallied While The FDA Approved OsteoDetect” on May 26, 2018.‘s news article titled: “Premarket analyst action – healthcare” with publication date: June 07, 2018 was also an interesting one.

Among 12 analysts covering The Medicines Co (NASDAQ:MDCO), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 38 analyst reports since August 28, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 5 by H.C. Wainwright. JP Morgan maintained the shares of MDCO in report on Saturday, August 29 with “Buy” rating. The firm earned “Buy” rating on Monday, January 22 by Citigroup. Citigroup maintained The Medicines Company (NASDAQ:MDCO) rating on Wednesday, July 26. Citigroup has “Neutral” rating and $45 target. The rating was maintained by RBC Capital Markets on Wednesday, November 16 with “Outperform”. Cowen & Co maintained the stock with “Buy” rating in Tuesday, October 10 report. On Thursday, February 22 the stock rating was maintained by Oppenheimer with “Hold”. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by H.C. Wainwright on Tuesday, July 25. The stock of The Medicines Company (NASDAQ:MDCO) has “Hold” rating given on Monday, August 28 by Oppenheimer. The firm has “Buy” rating given on Monday, August 31 by Leerink Swann.

The Medicines Company (NASDAQ:MDCO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *